Cargando…
PARP Inhibitors: A New Horizon for Patients with Prostate Cancer
The introduction of PARP inhibitors (PARPi) in prostate cancer is a milestone and provides a pathway to hope in fighting this disease. It is the first time that drugs, based on the concept of synthetic lethality, have been approved for prostate cancer. In addition, it is also the first time that gen...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9220343/ https://www.ncbi.nlm.nih.gov/pubmed/35740437 http://dx.doi.org/10.3390/biomedicines10061416 |